Recherche avancée
Affichage des résultats 941 à 960 sur 8263 au total
-
A Physiological Model to Evaluate Drug Kinetics in Patients with Hemorrhagic Shock Followed by Fluid Resuscitation
Michel Tod, Franck Lagneau, Vincent Jullien, Olivier Mimoz
-
Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy.
Benoit You, Paul Perrin, Gilles Freyer, Alain Ruffion, Brigitte Tranchand, Emilie Hénin, Philippe Paparel, Benjamin Ribba, Marian Devonec, Claire Falandry, Cécile Fournel, Michel Tod, Pascal Girard
-
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
Benoit You, Brigitte Tranchand, Pascal Girard, Claire Falandry, Benjamin Ribba, Sylvie Chabaud, Pierre-Jean Souquet, Isabelle Court-Fortune, Véronique Trillet-Lenoir, Cécile Fournel, Michel Tod, Gilles Freyer
-
Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid.
X. Delavenne, S. Laporte, S. Demasles, N. Mallouk, Michel Tod, Pascal Girard, P. Mismetti
-
2009 - Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin lymphoma
David Ternant, E. Henin, Guillaume Cartron, Michel Tod, Gilles Paintaud, Pascal Girard
-
Development of a drug - disease simulation model for rituximab in follicular non-Hodgkin lymphoma
David Ternant, E. Henin, Guillaume Cartron, Michel Tod, Gilles Paintaud, Pascal Girard
-
Chemotherapy may be delivered based on an integrated view of tumour dynamics.
Benjamin Ribba, Benoit You, Michel Tod, Pascal Girard, B. Tranchand, V. Trillet-Lenoir, G. Freyer
-
Development of a drug - disease simulation model for rituximab in follicular non-Hodgkin lymphoma
David Ternant, Emilie Henin, Guillaume Cartron, Michel Tod, Gilles Paintaud, Pascal Girard
-
Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma
David Ternant, Emilie Henin, Guillaume Cartron, Michel Tod, Gilles Paintaud, Pascal Girard
-
Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model
C. Gerard, Nathalie Bleyzac, Pascal Girard, G. Freyer, Y. Bertrand, M. Tod
-
Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.
Benoit You, M. Pollet-Villard, L. Fronton, C. Labrousse, A.-M. Schott, T. Hajri, Pascal Girard, G. Freyer, Michel Tod, B. Tranchand, O. Colomban, Benjamin Ribba, D. Raudrant, J. Massardier, Sylvie Chabaud, F. Golfier
-
Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
Benoit You, Ludivine Fronton, Helen Boyle, Jean-Pierre Droz, Pascal Girard, Brigitte Tranchand, Benjamin Ribba, Michel Tod, Sylvie Chabaud, Henri Coquelin, Aude Fléchon
-
A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers.
Benjamin Ribba, Emmanuel Watkin, Michel Tod, Pascal Girard, Emmanuel Grenier, Benoît You, Enrico Giraudo, Gilles Freyer
-
Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model
C. Gerard, Nathalie Bleyzac, Pascal Girard, G. Freyer, Y. Bertrand, M. Tod
-
Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4
Marion Bouillon-Pichault, Vincent Jullien, Caroline Bazzoli, Gérard Pons, Michel Tod
-
Model-based design of rituximab dosing optimization in follicular non-hodgkin lymphoma
David Ternant, Guillaume Cartron, E. Henin, Michel Tod, Pascal Girard, Gilles Paintaud
-
A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy
Dr Verstuyft, Xavier Delavenne, Alexandra Rousseau, Annie Robert, Michel Tod, Bertrand Diquet, Martine Lebot, Patrice Jaillon, Laurent Becquemont
-
A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection
A. Janoly-Dumenil, I. Rouvet, Nathalie Bleyzac, F. Morfin, Mt. Zabot, M. Tod
-
Prédiction quantitative des interactions médicamenteuses impliquant les cytochromes 3A4 et 2D6 : approche in vivo
Sylvain Goutelle, M. Tod
-
A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy.
Benjamin Ribba, Gentian Kaloshi, Mathieu Peyre, Damien Ricard, Vincent Calvez, Michel Tod, Branka Cajavec-Bernard, Ahmed Idbaih, Dimitri Psimaras, Linda Dainese, Johan Pallud, Stéphanie Cartalat-Carel, Jean-Yves Delattre, Jérôme Honnorat, Emmanuel Grenier, François Ducray